IFRS 2 Part 5: Cash-Settled Awards and Choice-of-Settlement Transactions
Part 5 of a 7-part series on IFRS 2: share appreciation rights, liability remeasurement, and how counterparty choice versus entity choice changes the accounting.
Quick Summary
- Cash-settled transactions — such as share appreciation rights (SARs) — create a liability, not equity, and that liability is remeasured to fair value at every reporting date and at settlement, with all changes going through profit or loss.
- This is the opposite of the equity-settled rule: where equity-settled fair value is fixed forever at grant date, cash-settled fair value is never fixed — it moves every period until the liability is paid.
- Choice-of-settlement awards split into two very different cases depending on who holds the choice: the counterparty, or the entity.
- Counterparty choice typically creates a compound financial instrument with separate debt and equity components; entity choice depends on whether the entity has a present obligation to settle in cash.
SHARE-BASED PAYMENT — 7 GUIDES
Cash-Settled Share-Based Payments
In a cash-settled transaction, the entity receives goods or services and, instead of issuing equity, pays cash calculated by reference to the price (or value) of its equity instruments. The most common example is a share appreciation right (SAR): an employee is entitled to a future cash payment equal to the increase in the entity’s share price above a set price, over a specified period.
Because no equity instrument is ever issued, the entity recognizes a liability rather than an increase in equity. That liability is measured at fair value both at grant date and at every subsequent reporting date up to and including the date of settlement, with any change in fair value recognized in profit or loss for the period. This remeasurement is the single biggest practical difference from equity-settled awards.
| Equity-Settled | Cash-Settled | |
|---|---|---|
| Balance sheet credit | Equity | Liability |
| Fair value measured | Once, at grant date | At every reporting date and at settlement |
| Where fair-value changes go | Nowhere — fair value never changes | Profit or loss, every period |
| Vesting-condition true-up | Number expected to vest only | Number expected to vest, and fair value itself |
Worked Example: A Share Appreciation Right
On 1 January 2024, an entity grants 500 employees 100 SARs each (50,000 SARs), entitling each employee to a cash payment equal to the increase in the entity’s share price above $50, provided the employee remains in service for three years. At the end of 2024, the fair value per SAR is $8 and 480 employees are expected to qualify. At the end of 2025, fair value has risen to $11 and the estimate is revised to 470 employees. At the end of 2026 (vesting date), fair value is $14 and 465 employees actually qualify.
| Year | Fair Value / SAR | Cumulative Liability | Expense for the Year |
|---|---|---|---|
| 2024 | $8 | 48,000 × $8 × 1/3 = $128,000 | $128,000 |
| 2025 | $11 | 47,000 × $11 × 2/3 = $344,667 | $216,667 |
| 2026 | $14 | 46,500 × $14 × 3/3 = $651,000 | $306,333 |
Every year, both the headcount estimate and the fair value itself feed into the cumulative liability — the double true-up that makes cash-settled awards more volatile in profit or loss than their equity-settled equivalents. At settlement, the liability is derecognized as cash is paid out.
Transactions With a Choice of Settlement
Some arrangements allow either the entity or the counterparty to choose whether the transaction is settled in cash or by issuing equity instruments. IFRS 2 treats these very differently depending on who holds that choice.
Counterparty Has the Choice
When the counterparty can choose the settlement form, the entity has granted a compound financial instrument — in substance, a debt component (the counterparty’s right to demand cash) plus an equity component (the counterparty’s right to demand shares instead). The entity measures the fair value of the compound instrument at grant date, measures the debt component first (usually as the fair value of the cash alternative), and derives the equity component as the residual — the difference between the fair value of the compound instrument as a whole and the fair value of the debt component.
Why measure the residual, not the equity component directly? This mirrors the general approach IFRS uses for compound instruments elsewhere (for example, convertible bonds under IAS 32) — the cash-settlement alternative is usually the easier component to value directly, so the equity option’s incremental value is captured as whatever is left over.
The debt component is subsequently remeasured at fair value through profit or loss each period, like any other cash-settled liability, until it is settled. If the instrument is ultimately settled in equity, the previously recognized liability is transferred into equity at the date of settlement rather than reversed through profit or loss.
Entity Has the Choice
When the entity chooses the settlement form, the transaction is accounted for as an equity-settled transaction — with grant-date fair value fixed and never remeasured — unless the entity has a present obligation to settle in cash, whether contractual or constructive (for example, because it has a consistent past practice of settling similar awards in cash, creating a valid expectation). If a present obligation to pay cash exists, the transaction is accounted for as cash-settled instead, regardless of how the plan is worded.
| Who Chooses | Default Treatment | Exception |
|---|---|---|
| Counterparty | Compound instrument — split into debt and equity components | None — always split |
| Entity | Equity-settled | Cash-settled, if the entity has a present obligation to pay cash |
Why This Distinction Matters Beyond the Accounting Entries
The equity-versus-liability classification is not a cosmetic bookkeeping choice. A liability-classified award introduces earnings volatility that persists for the entire life of the award — every movement in share price flows through profit or loss until final settlement — while an equity-classified award, once measured at grant date, cannot generate any further income-statement volatility at all from changes in share price. Two economically similar plans, structured differently, can produce materially different reported earnings over their life, which is exactly why IFRS 2 pays such close attention to who holds the settlement choice and whether a present obligation to pay cash actually exists.
Need Help With Share-Based Payment Accounting?
From designing an equity incentive plan through valuing options and preparing the disclosures, our team can help you apply IFRS 2 correctly. Contact our Financial Advisory team today.